Literature DB >> 389036

Streptococcal pharyngitis therapy. A comparison of two erythromycin formulations.

C W Derrick, H C Dillon.   

Abstract

The recommended dosage of erythromycin, without regard to the formulation prescribed, for children with streptococcal pharyngitis is 30 to 40 mg/kg/day. We previously reported an acceptable streptococcal eradication rate among patients with pharyngitis treated with erythromycin estolate, 20 mg/kg/day. In this study, an extension of the earlier one, the efficacy of this same dosage of erythromycin estolate was compared with a 40 mg/kg/day dosage of erythromycin ethylsuccinate. Streptococcal eradication rates were nearly identical in the two groups of patients. The efficacy of erythromycin estolate at a dosage lower than that recommended for children is most likely explained on pharmacologic grounds: better absorption and higher levels in serum and tissue than those achieved with other erythromycin formulations. It seems rational to calculate required dosages of erythromycin on the basis of the formulation being administered.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 389036     DOI: 10.1001/archpedi.1979.02130110054008

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  3 in total

1.  Five days of erythromycin estolate versus ten days of penicillin V in the treatment of group A streptococcal tonsillopharyngitis in children. Pharyngitis Study Group.

Authors:  D Adam; H Scholz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-09       Impact factor: 3.267

2.  Plasma bactericidal activity after administration of erythromycin estolate and erythromycin ethylsuccinate to healthy volunteers.

Authors:  D Bérubé; D Kirouac; D Croteau; M G Bergeron; M Lebel
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

3.  Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography.

Authors:  D Croteau; M G Bergeron; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.